344 related articles for article (PubMed ID: 12489023)
1. Prospects for CD40-directed experimental therapy of human cancer.
Tong AW; Stone MJ
Cancer Gene Ther; 2003 Jan; 10(1):1-13. PubMed ID: 12489023
[TBL] [Abstract][Full Text] [Related]
2. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.
Tong AW; Papayoti MH; Netto G; Armstrong DT; Ordonez G; Lawson JM; Stone MJ
Clin Cancer Res; 2001 Mar; 7(3):691-703. PubMed ID: 11297266
[TBL] [Abstract][Full Text] [Related]
3. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
Loskog A; Tötterman TH; Böhle A; Brandau S
Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
[TBL] [Abstract][Full Text] [Related]
4. Gene transfer of CD40-ligand to dendritic cells stimulates interferon-gamma production to induce growth arrest and apoptosis of tumor cells.
Tomihara K; Kato K; Masuta Y; Nakamura K; Uchida H; Sasaki K; Tanaka T; Huang J; Hiratsuka H; Hamada H
Gene Ther; 2008 Feb; 15(3):203-13. PubMed ID: 17989706
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas.
Vardouli L; Lindqvist C; Vlahou K; Loskog AS; Eliopoulos AG
Cancer Gene Ther; 2009 Nov; 16(11):848-60. PubMed ID: 19461675
[TBL] [Abstract][Full Text] [Related]
6. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154.
Mackey MF; Gunn JR; Ting PP; Kikutani H; Dranoff G; Noelle RJ; Barth RJ
Cancer Res; 1997 Jul; 57(13):2569-74. PubMed ID: 9205055
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells.
Gomes EM; Rodrigues MS; Phadke AP; Butcher LD; Starling C; Chen S; Chang D; Hernandez-Alcoceba R; Newman JT; Stone MJ; Tong AW
Clin Cancer Res; 2009 Feb; 15(4):1317-25. PubMed ID: 19228733
[TBL] [Abstract][Full Text] [Related]
8. CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction.
Wagner AH; Güldenzoph B; Lienenlüke B; Hecker M
Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):715-20. PubMed ID: 14976003
[TBL] [Abstract][Full Text] [Related]
9. Adeno-associated virus mediated gene transfer into lung cancer cells promoting CD40 ligand-based immunotherapy.
Wu JQ; Zhao WH; Li Y; Zhu B; Yin KS
Virology; 2007 Nov; 368(2):309-16. PubMed ID: 17675129
[TBL] [Abstract][Full Text] [Related]
10. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
[TBL] [Abstract][Full Text] [Related]
11. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of CD40 with juxtacrine activity in human nonsmall lung cancer cells correlates with poor prognosis.
Ishikawa K; Miyamoto M; Yoshioka T; Kato T; Kaji M; Ohbuchi T; Hirano S; Itoh T; Dosaka-Akita H; Kondo S
Cancer; 2008 Aug; 113(3):530-41. PubMed ID: 18548529
[TBL] [Abstract][Full Text] [Related]
13. Increase of in vivo antitumoral activity by CD40L (CD154) gene transfer into pancreatic tumor cell-dendritic cell hybrids.
Ziske C; Etzrodt PE; Eliu AS; Gorschlüter M; Strehl J; Flieger D; Messmer D; Schmitz V; Gonzalez-Carmona MA; Sievers E; Brossart P; Sauerbruch T; Schmidt-Wolf IG
Pancreas; 2009 Oct; 38(7):758-65. PubMed ID: 19546834
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
Liu Y; Xia D; Li F; Zheng C; Xiang J
Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183
[TBL] [Abstract][Full Text] [Related]
15. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C
Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328
[TBL] [Abstract][Full Text] [Related]
16. CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis.
Zhou F; Ajuebor MN; Beck PL; Le T; Hogaboam CM; Swain MG
Hepatology; 2005 Aug; 42(2):372-80. PubMed ID: 16025512
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells require maturation via CD40 to generate protective antitumor immunity.
Mackey MF; Gunn JR; Maliszewsky C; Kikutani H; Noelle RJ; Barth RJ
J Immunol; 1998 Sep; 161(5):2094-8. PubMed ID: 9725199
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease.
Howard LM; Miller SD
Autoimmunity; 2004 Aug; 37(5):411-8. PubMed ID: 15621565
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.
Couderc B; Zitvogel L; Douin-Echinard V; Djennane L; Tahara H; Favre G; Lotze MT; Robbins PD
Cancer Gene Ther; 1998; 5(3):163-75. PubMed ID: 9622100
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy.
Bereznaya NM; Chekhun VF
Exp Oncol; 2007 Mar; 29(1):2-12. PubMed ID: 17431381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
